View Older Stories View More Recent Stories
-
Edwards Lifesciences (EW) PT Lowered to $85 at Stifel
-
Edwards Lifesciences (EW) 5900 contracts of January 85 calls trade
-
Edwards Lifesciences (EW) PT Raised to $85 at Leerink Partners
-
FTC moves to block Edwards Lifesciences acquisition of JenaValve
-
BTIG Upgrades Edwards Lifesciences (EW) to Buy
-
Edwards Lifesciences (EW) PT Raised to $85 at Bernstein
-
Edwards Lifesciences (EW) PT Raised to $85 at UBS
-
Edwards Lifesciences (EW) PT Raised at TD Cowen After a Beat-And-Raise Performance
-
Edwards Lifesciences (EW) PT Raised at RBC Capital Amid Double-Digit Growth
-
Edwards Lifesciences (EW) PT Raised at Piper Sandler Following 'Strong Q2 Report Across-The-Board'
-
Edwards Lifesciences (EW) PT Raised to $95 at Stifel
-
Edwards Lifesciences (EW) PT Raised to $95 at Mizuho
-
Edwards Lifesciences (EW) PT Raised to $81 at Canaccord Genuity
-
Edwards Lifesciences (EW) PT Raised to $84 at Leerink Partners
-
Edwards Lifesciences (EW) Announces Resignation of Larry L. Wood, Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart
-
Oppenheimer Reiterates Outperform Rating on Edwards Lifesciences (EW)
-
William Blair Reiterates Outperform Rating on Edwards Lifesciences (EW)
-
After-hours movers: Edwards Lifesciences, Intel, Deckers Brands and more
-
Edwards Lifesciences (EW) Tops Q2 EPS by 5c; offers guidance
-
FDA: Edwards Lifesciences (EW) is recalling arterial cannula due to risk of wire exposure
-
Edwards Lifesciences (EW) Files Mixed Shelf
-
Nephron Upgrades Edwards Lifesciences (EW) to Buy
-
Argus Starts Edwards Lifesciences (EW) at Buy
-
Canaccord Genuity Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Citi Reiterates 'Top Pick' on Boston Scientific (BSX)
-
Edwards Lifesciences (EW) gains after Boston Scientific (BSX) ends worldwide sales of the ACURATE neo2 and ACURATE Prime
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Edwards Lifesciences (EW) Added as Top Pick at Citi, PODD Removed
-
Edwards Lifesciences (EW) PT Raised to $83 at Piper Sandler
-
Edwards Lifesciences (EW) TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
Piper Sandler Upgrades Edwards Lifesciences (EW) to Overweight
-
Edwards Lifesciences (EW) Tops Q1 EPS by 4c, Offers Guidance
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) PT Raised to $71 at Canaccord Genuity
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance
-
Stifel Upgrades Edwards Lifesciences (EW) to Buy
-
Wolfe Research Downgrades Edwards Lifesciences (EW) to Underperform
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of Edwards Lifesciences Corporation (EW)
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
BofA Securities Upgrades Edwards Lifesciences (EW) to Buy

